[시장보고서]미국의 저분자 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 서비스별, 치료 영역별, 최종 용도별, 부문 예측(2025-2033년)

미국의 저분자 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 서비스별, 치료 영역별, 최종 용도별, 부문 예측(2025-2033년)

U.S. Small Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow, By Service, By Therapeutics Area, By End Use, And Segment Forecasts, 2025 - 2033

상품코드 : 1790211

리서치사 : Grand View Research

발행일 : 2025년 07월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,950

￦ 5,691,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 4,950

￦ 7,131,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 6,950

￦ 10,013,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

미국의 저분자 신약개발 아웃소싱 시장 개요

미국의 저분자 신약개발 아웃소싱 시장 규모는 2024년 15억 2,000만 달러로 평가되었습니다. 2033년에는 34억 7,000만 달러에 달하고, 2025-2033년 연평균 9.7% 성장할 것으로 예측됩니다. R&D 비용 증가, 초기 단계의 연구 활동에 대한 관심 증가, 내부 자원이 한정된 생명공학 기업의 성장이 시장을 주도하고 있습니다.

또한, 아웃소싱은 제약 및 생명공학 기업들에게 타임라인 단축, 고정 간접비 절감, 제약 화학, 히트-투-리드 최적화, ADME/PK 검사, IND 획득 활동 등의 부문에서 전문성을 확보하기 위한 전략적 선택으로 부상하고 있습니다. 전략적 선택으로 부상하고 있습니다.

AI를 활용한 화합물 설계, CRISPR을 활용한 표적 검증, 고성능 스크리닝, 3D 세포 모델 등 혁신적인 기술을 통해 신약개발 프로세스를 혁신하고, CRO(임상시험수탁기관)가 보다 효율적이고 예측 가능한 결과를 제공할 수 있게 됩니다. 또한, 연구개발비용의 상승, 의약품 개발 수요 증가, 가상 의약품 모델로의 전환이 시장을 뒷받침하고 있습니다. 또한, 등록 임상시험 증가, 저분자 의약품의 승인률 증가, 의료 기술의 발전, 연구 대상 질환 증가, 새로운 치료법에 대한 긴급한 요구가 시장을 주도할 것으로 예측됩니다.

시장 계통 전망
- 상위 시장 전망
- 관련/보조 시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
임상 검사 건수 분석(2024년)
- 국가별 임상시험 건수
- 상별 임상시험 건수
- 연구 디자인별 임상시험 건수
- 주요 치료 영역별 임상시험 건수
가격 모델 분석
기술
시장 분석 툴
- Porter의 Five Forces 분석
- SWOT 분석에 의한 PESTEL

제4장 미국의 저분자 Drug Discovery 아웃소싱 시장 : 워크플로우별, 추정·동향 분석

미국의 저분자 Drug Discovery 아웃소싱 시장(워크플로우별) : 부문 대시보드
미국의 저분자 Drug Discovery 아웃소싱 시장(워크플로우별) : 변동 분석
워크플로우별, 2021-2033년
대상 특정 및 스크리닝
대상 검증 및 기능 정보과학
리드 특정 및 후보자 최적화
전임상 개발
기타

제5장 미국의 저분자 Drug Discovery 아웃소싱 시장 : 서비스별, 추정·동향 분석

미국의 저분자 Drug Discovery 아웃소싱 시장(서비스별) : 부문 대시보드
미국의 저분자 Drug Discovery 아웃소싱 시장(서비스별) : 변동 분석
서비스별, 2021-2033년
화학 서비스
생물학 서비스

제6장 미국의 저분자 Drug Discovery 아웃소싱 시장 : 치료 영역별, 추정·동향 분석

미국의 저분자 Drug Discovery 아웃소싱 시장(치료 영역별) : 부문 대시보드
미국의 저분자 Drug Discovery 아웃소싱 시장(치료 영역별) : 변동 분석
치료 영역별, 2021-2033년
호흡기
통증과 마취
종양학
안과
혈액학
심혈관계
내분비
위장
면역 조절
항감염성
중추신경계
피부과
비뇨생식기계

제7장 미국의 저분자 Drug Discovery 아웃소싱 시장 : 최종 용도별, 추정·동향 분석

미국의 저분자 Drug Discovery 아웃소싱 시장(최종 용도별) : 부문 대시보드
미국의 저분자 Drug Discovery 아웃소싱 시장(최종 용도별) : 변동 분석
용도별, 2021-2033년
제약 바이오테크놀러지 기업
학술기관

제8장 경쟁 구도

시장 진출기업 분류
- 마켓 리더
- 신흥 참여 기업
기업의 시장 점유율/평가 분석, 2024년
기업 개요
- Charles River Laboratories
- Laboratory Corporation of America Holdings(Covance)
- Albany Molecular Research(Curia)
- Merck & Co., Inc.
- QIAGEN
- Eurofins
- Evotec
- GenScript BIoTech
- Pharmaron
- Syngene International
- Dalton Pharma Services
- Oncodesign
- Jubilant Biosys
- Domainex
- Dr. Reddy Laboratories Ltd.
- Pharmaron Beijing Co., Ltd.
- TCG Lifesciences Pvt Ltd.

제9장 주요 추천 사항

LSH

영문 목차

영문목차

U.S. Small Molecule Drug Discovery Outsourcing Market Summary

The U.S. small molecule drug discovery outsourcing market size was estimated at USD 1.52 billion in 2024 and is projected to reach USD 3.47 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. Increasing R&D expenses, rising focus on early-stage research activities, and growing biotech companies with limited in-house resources drive the market.

Besides, outsourcing has emerged as a strategic option for pharmaceutical and biotech companies aiming to accelerate the timelines, lower fixed overhead costs, and gain access to specialized expertise in areas such as medicinal chemistry, hit-to-lead optimization, ADME/PK studies, and IND-enabling activities.

Innovations like AI-driven compound design, CRISPR-based target validation, high-throughput screening, and 3D cell models transform discovery processes, enabling contract research organizations (CROs) to provide more efficient and predictive results. Furthermore, rising R&D costs, increased demand for drug development, and a shift towards virtual pharmaceutical models support the market. In addition, an increase in registered clinical studies, a higher approval rate for small molecule drugs, advancements in medical technology, a rise in diseases being studied, and the urgent need for new treatments are anticipated to drive the market.

U.S. Small Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. small molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, and end use:

Workflow Outlook (Revenue, USD Million, 2021 - 2033)
Target Identification & Screening
Target Validation & Functional Informatics
Lead Identification & Candidate Optimization
Preclinical Development
Others
Service Outlook (Revenue, USD Million, 2021 - 2033)
Chemistry Services
Biology Services
Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
Respiratory system
Pain and Anesthesia
Oncology
Ophthalmology
Hematology
Cardiovascular
Endocrine
Gastrointestinal
Immunomodulation
Anti-infective
Central Nervous System
Dermatology
Genitourinary System
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & Biotechnology companies
Academic Institutes

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Workflow
- 1.2.2. Service
- 1.2.3. Therapeutics Area
- 1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain-based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. Small Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Increasing demand for outsourcing services in drug development
  - 3.2.1.2. Technological advancements in drug discovery
  - 3.2.1.3. Rising shortening time-to-market pressures
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Intellectual property (IP) and data security concerns
  - 3.2.2.2. Limited standardization and reproducibility
3.3. Clinical Trials Volume Analysis, (2024)
- 3.3.1. Total Number Of Clinical Trials By Country
- 3.3.2. Total Number Of Clinical Trials, By Phase
- 3.3.3. Total Number Of Clinical Trials, By Study Design
- 3.3.4. Total Number Of Clinical Trials, By Key Therapeutic Area
3.4. Pricing Model Analysis
3.5. Technology Landscape
3.6. Market Analysis Tools
- 3.6.1. Porter's Five Forces Analysis
- 3.6.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Small Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

4.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
4.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
4.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
4.4. Target Identification & Screening
- 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Target Validation & Functional Informatics
- 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Lead Identification & Candidate Optimization
- 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Preclinical Development
- 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Others
- 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Small Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

5.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Service: Segment Dashboard
5.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Service: Movement Analysis
5.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
5.4. Chemistry Services
- 5.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Biology Services
- 5.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Small Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

6.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
6.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
6.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
6.4. Respiratory system
- 6.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Pain and Anesthesia
- 6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Oncology
- 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Ophthalmology
- 6.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Hematology
- 6.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Cardiovascular
- 6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Endocrine
- 6.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Gastrointestinal
- 6.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.12. Immunomodulation
- 6.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.13. Anti-infective
- 6.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.14. Central Nervous System
- 6.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.15. Dermatology
- 6.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.16. Genitourinary System
- 6.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Small Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

7.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
7.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By End Use: Movement Analysis
7.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
7.4. Pharmaceutical & Biotechnology companies
- 7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Academic Institutes
- 7.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
8.2. Company Market Share/Assessment Analysis, 2024
8.3. Company Profiles
- 8.3.1. Charles River Laboratories
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Financial Performance
  - 8.3.1.3. Service Benchmarking
  - 8.3.1.4. Strategic Initiatives
- 8.3.2. Laboratory Corporation of America Holdings (Covance)
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Financial Performance
  - 8.3.2.3. Service Benchmarking
  - 8.3.2.4. Strategic Initiatives
- 8.3.3. Albany Molecular Research (Curia)
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Financial Performance
  - 8.3.3.3. Service Benchmarking
  - 8.3.3.4. Strategic Initiatives
- 8.3.4. Merck & Co., Inc.
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Financial Performance
  - 8.3.4.3. Service Benchmarking
  - 8.3.4.4. Strategic Initiatives
- 8.3.5. QIAGEN
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Financial Performance
  - 8.3.5.3. Service Benchmarking
  - 8.3.5.4. Strategic Initiatives
- 8.3.6. Eurofins
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Financial Performance
  - 8.3.6.3. Service Benchmarking
  - 8.3.6.4. Strategic Initiatives
- 8.3.7. Evotec
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Financial Performance
  - 8.3.7.3. Service Benchmarking
  - 8.3.7.4. Strategic Initiatives
- 8.3.8. GenScript Biotech
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Financial Performance
  - 8.3.8.3. Service Benchmarking
  - 8.3.8.4. Strategic Initiatives
- 8.3.9. Pharmaron
  - 8.3.9.1. Company Overview
  - 8.3.9.2. Financial Performance
  - 8.3.9.3. Service Benchmarking
  - 8.3.9.4. Strategic Initiatives
- 8.3.10. Syngene International
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Financial Performance
  - 8.3.10.3. Service Benchmarking
  - 8.3.10.4. Strategic Initiatives
- 8.3.11. Dalton Pharma Services
  - 8.3.11.1. Company Overview
  - 8.3.11.2. Financial Performance
  - 8.3.11.3. Service Benchmarking
  - 8.3.11.4. Strategic Initiatives
- 8.3.12. Oncodesign
  - 8.3.12.1. Company Overview
  - 8.3.12.2. Financial Performance
  - 8.3.12.3. Service Benchmarking
  - 8.3.12.4. Strategic Initiatives
- 8.3.13. Jubilant Biosys
  - 8.3.13.1. Company Overview
  - 8.3.13.2. Financial Performance
  - 8.3.13.3. Service Benchmarking
  - 8.3.13.4. Strategic Initiatives
- 8.3.14. Domainex
  - 8.3.14.1. Company Overview
  - 8.3.14.2. Financial Performance
  - 8.3.14.3. Service Benchmarking
  - 8.3.14.4. Strategic Initiatives
- 8.3.15. Dr. Reddy Laboratories Ltd.
  - 8.3.15.1. Company Overview
  - 8.3.15.2. Financial Performance
  - 8.3.15.3. Service Benchmarking
  - 8.3.15.4. Strategic Initiatives
- 8.3.16. Pharmaron Beijing Co., Ltd.
  - 8.3.16.1. Company Overview
  - 8.3.16.2. Financial Performance
  - 8.3.16.3. Service Benchmarking
  - 8.3.16.4. Strategic Initiatives
- 8.3.17. TCG Lifesciences Pvt Ltd.
  - 8.3.17.1. Company Overview
  - 8.3.17.2. Financial Performance
  - 8.3.17.3. Service Benchmarking
  - 8.3.17.4. Strategic Initiatives